SCHEMBL20129239

SCHEMBL20129239

Cn1c2ccncc2c2ccc(-c3ccc(N4CC(OCCOCCOCCOCCOCc5ccccc5)C4)nc3)cc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 3/20 0.37
NTRK1 P04629 2/20 0.35
FAAH O00519 1/20 0.33
METAP2 P50579 1/20 0.33
NPC1 O15118 1/20 0.33
POLB P06746 1/20 0.33
GAA P10253 1/20 0.33
RAB9A P51151 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33
LIPG Q9Y5X9 1/20 0.33
PDE10A Q9Y233 2/20 0.32
GPR39 O43194 1/20 0.32
ALK Q9UM73 1/20 0.32
ACACB O00763 1/20 0.32
GBA1 P04062 1/20 0.31
UGCG Q16739 1/20 0.31
GBA2 Q9HCG7 1/20 0.31
AOC3 Q16853 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20129238 0.88 RET (0.35) RETMETAP2NPC1POLBGAA
SCHEMBL27097863 0.87 METAP2 (0.34) RETMETAP2NPC1POLBGAA
SCHEMBL20128934 0.85 FAAH (0.40) FAAHNPC1POLBGAARAB9A
SCHEMBL20129237 0.82 METAP2 (0.31) RETMETAP2
SCHEMBL22906858 0.79 LIPG (0.38) LIPG
SCHEMBL27098347 0.79 GRIN2B (0.41) RETNPC1RAB9AHDAC1HDAC2
SCHEMBL20128974 0.78 ATM (0.40) METAP2NPC1POLBGAARAB9A
SCHEMBL20128962 0.77 ATM (0.36) METAP2NAAA
SCHEMBL22907330 0.77 MAPT (0.36) RETMETAP2NPC1POLBGAA
SCHEMBL20129242 0.77 FAAH (0.37) FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
WO-2021011913-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2021-01-21 WO disclosed
WO-2018102067-A2 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE Arvinas, Inc. (US) 2018-06-07 WO disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN RET 214/4885NTRK1 2162/4885FAAH 4345/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 RET 305/4885NTRK1 2836/4885FAAH 4290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.